A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese Participants

Exclusion Criteria

• •Participant has a known hypersensitivity to any components of the investigational medicinal product (IMP) or other biologic drugs or humanized antibodies (mAbs)
• •Participant has clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe posttreatment hypersensitivity reactions
• •Participant has abnormal blood pressure (BP) (outside the normal range)
• •Participant has alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) \>1.5x upper limit of normal (ULN)
• •Participant has a recent history or currently active clinically-significant bacterial, fungal, endoparasite, or viral (including hospitalization for coronavirus disease 2019 (COVID-19)) infection (within 6 months of the Screening Visit)
• •Participant has a history of inflammatory bowel disease (includes Crohn's disease and ulcerative colitis)
• •Participant has a history of diabetes
• •Study participant has a corrected QT interval (QTc) \>450msec for male study participants or \>470msec for female study participants
• •Participant has sensitivity to heparin or heparin-induced thrombocytopenia
• •Participant has a positive test for substance of abuse, or is a regular alcohol consumer defined as an average weekly intake of \>14 units
• •Participant has received any prescription or nonprescription medicines within 14 days (or 5 half-lives of the respective drug, whichever is longer) prior to the Baseline Visit, other than contraceptives or occasional use of analgesic
• •Participant has received Bacillus Calmette-Guerin vaccinations within 1 year prior to the Baseline Visit or within 90 days after the final dose of investigational medicinal product (IMP)
• •Participant has been treated with biologic agents (such as mAbs, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to the Baseline Visit
• •Participant has participated in another study of an IMP within the previous 90 days or 5 half-lives of the IMP (whichever longer), or is currently participating in another study of an IMP